Presbyopia eye drops establish as a real category
Pilocarpine and miotic-class drops for presbyopia are settling into a routine commercial category with established prescribing patterns.
Presbyopia eye drops launched with skepticism about whether the convenience would justify daily use. Three years of real-world data show the category has found a routine prescribing tier in patients who prefer drops to readers or contact lenses. The next-generation programs targeting longer durability and reduced side-effect profile will define category growth from here.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is thyroid eye disease?